$5.40
Today
as of Jul 22, 16:56 ET
Last 30 days
Recent Press Releases & News
William Blair Starts Zura Bio (ZURA) at Outperform
William Blair Initiates Zura Bio at Outperform
Zura Bio Exceeds Enrollment Targets for Phase 2 Trials in Hidradenitis Suppurativa, Systemic Sclerosis
Overview
52-week range
$1.00
$7.44
68% of range
Avg surprise (last 3)
-10.2%
Avg reaction (last 2)
-2.4%
50% positive
Latest IV / EM
202%
EM ±46.3% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.22 | $-0.17 | -29.4% | -15.8% | -7.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.17 | $-0.19 | +10.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.19 | $-0.17 | -11.8% | — | +2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.26 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.17 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.18 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.31 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.20 | -$0.17 | -17.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-25M | — | $-20M | $-18M | $-19M | — | $-19M | $-12M |
| Net income | $-24M | — | $-18M | $-16M | $-17M | — | $-21M | $-10M |
| EPS (diluted) | $-0.22 | — | $-0.21 | $-0.17 | $-0.19 | — | $-0.26 | $-0.17 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $226M | $109M | $139M | $154M | $171M | $176M | $188M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $227M | $112M | $142M | $157M | $172M | $179M | $189M | $189M |
| Total assets | $229M | $114M | $144M | $158M | $172M | $180M | $189M | $190M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $12M | $12M | $25M | $19M | $21M | $20M | $18M | $17M |
| Total equity | — | — | $108M | $126M | $138M | $147M | $153M | $157M |